5-Chloro-2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid 1,1-dimethylethyl ester | 161468-55-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 5-Chloro-2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid 1,1-dimethylethyl ester
• 英文别名: tert-butyl 5-chloro-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-1-carboxylate；tert-butyl 5-chloro-2-oxo-2,3-dihydrobenzimidazole-1-carboxylate；tert-butyl 5-chloro-2-oxo-3H-benzimidazole-1-carboxylate
• CAS: 161468-55-9
• 化学式: C₁₂H₁₃ClN₂O₃
• 分子量: 268.7
• InChiKey: FQYAYLGIKTZELO-UHFFFAOYSA-N

物化性质

• 密度：
  1.335±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-Chloro-2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid 1,1-dimethylethyl ester 在 potassium carbonate 、 三氟乙酸 作用下， 以 乙腈 为溶剂， 生成 3-苄基-5-氯-1H-苯并咪唑-2-酮
  参考文献：
  名称：

  Regiospecific Functionalization of 1,3-Dihydro-2H-benzimidazol-2-one and Structurally Related Cyclic Urea Derivatives

  摘要：

  Methods for selectively protecting one of the degenerate nitrogen atoms of the cyclic urea derivatives 1,3-dihydro-2H-benzimidazol-2-one (6a), 1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (11), 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones (20), 1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one (22), and 1,3-dihydro-4-phenyl-2H-imidazol-2-one (27) were developed. Heating these cyclic ureas with ethyl 2-pyridyl carbonate in the presence of a base in CH3CN at reflux or DMF at 100 degrees C cleanly provided the monoethoxycarbonyl derivatives 7a, 12, 21, 23, and 28, respectively. Alternatively, treatment of 6a with an excess of diethyl pyrocarbonate or di-tert-butyl dicarbonate afforded the bis-alkoxycarbonyl derivatives 8a and 8b, respectively, which underwent disproportionation to 7a and 7b upon heating with 1 mol equiv of 6a and K2CO3 in CH3CN at reflux. The regiochemistry of the introduction of alkoxycarbonyl groups to benzimidazol-2-one derivatives was not significantly influenced by an electron-withdrawing (CF3, 6b) or an electron-donating (OCH3, 6c) substituent at C-5 of the heterocyclic ring. However, the reaction was found to be sensitive to steric factors since a chlorine substituent ortho to one of the urea N atoms (6e) completely directed the alkoxycarbonyl moiety to the less sterically encumbered N atom, affording a single product (7f, 7g). Alkylation of 7a-g proceeded efficiently to provide products 10a-10ag after removal of the protecting group. Halogenation of monoprotected benzimidazol-2-one 7a occurred regiospecifically to give the monohalo derivatives 7h, 7i, and 7k, the identity of which were readily established from the characteristic chemical shift and spin coupling pattern in their 1H NMR spectra. A protecting group interchange strategy that took advantage of the distinctive chemical reactivities of the EtO(2)C and t-BuO(2)C protecting groups toward isopropylamine was developed that provided access to the isomerically substituted series of monohalo, mono-N-alkylated benzimidazol-2-ones 71 and 7m. The efficient derivatization of the unprotected N atom of these monoprotected cyclic urea derivatives was accomplished by treating with activated and unactivated halides in the. presence of K2CO3 or exposure to alcohols under Mitsunobu conditions. In several cases, mixtures of O- and N-alkylated products were produced which were readily separated by chromatography. Alkylation of 7h with activated halides, using K2CO3 in CH3CN at reflux, occurred without protecting group equilibration; however, a mixture of isomeric alkylated products was obtained when 7h was heated at 110 degrees C in DMF with cyclohexylmethyl bromide in the presence of K2CO3 as the base. Derivatization of 7h under Mitsunobu reaction conditions proceeded with retention of the topological substituent relationships. Subsequent removal of the alkoxycarbonyl moiety afforded monoalkylated cyclic urea derivatives.

  DOI：

  10.1021/jo00111a014
• 作为产物：
  描述：

  2-羟基苯并咪唑 在 4-二甲氨基吡啶 、 磺酰氯 、 potassium carbonate 、 异丙胺 作用下， 以 四氢呋喃 、 溶剂黄146 、 乙腈 为溶剂， 反应 2.58h， 生成 5-Chloro-2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid 1,1-dimethylethyl ester
  参考文献：
  名称：

  Regiospecific Functionalization of 1,3-Dihydro-2H-benzimidazol-2-one and Structurally Related Cyclic Urea Derivatives

  摘要：

  Methods for selectively protecting one of the degenerate nitrogen atoms of the cyclic urea derivatives 1,3-dihydro-2H-benzimidazol-2-one (6a), 1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (11), 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones (20), 1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one (22), and 1,3-dihydro-4-phenyl-2H-imidazol-2-one (27) were developed. Heating these cyclic ureas with ethyl 2-pyridyl carbonate in the presence of a base in CH3CN at reflux or DMF at 100 degrees C cleanly provided the monoethoxycarbonyl derivatives 7a, 12, 21, 23, and 28, respectively. Alternatively, treatment of 6a with an excess of diethyl pyrocarbonate or di-tert-butyl dicarbonate afforded the bis-alkoxycarbonyl derivatives 8a and 8b, respectively, which underwent disproportionation to 7a and 7b upon heating with 1 mol equiv of 6a and K2CO3 in CH3CN at reflux. The regiochemistry of the introduction of alkoxycarbonyl groups to benzimidazol-2-one derivatives was not significantly influenced by an electron-withdrawing (CF3, 6b) or an electron-donating (OCH3, 6c) substituent at C-5 of the heterocyclic ring. However, the reaction was found to be sensitive to steric factors since a chlorine substituent ortho to one of the urea N atoms (6e) completely directed the alkoxycarbonyl moiety to the less sterically encumbered N atom, affording a single product (7f, 7g). Alkylation of 7a-g proceeded efficiently to provide products 10a-10ag after removal of the protecting group. Halogenation of monoprotected benzimidazol-2-one 7a occurred regiospecifically to give the monohalo derivatives 7h, 7i, and 7k, the identity of which were readily established from the characteristic chemical shift and spin coupling pattern in their 1H NMR spectra. A protecting group interchange strategy that took advantage of the distinctive chemical reactivities of the EtO(2)C and t-BuO(2)C protecting groups toward isopropylamine was developed that provided access to the isomerically substituted series of monohalo, mono-N-alkylated benzimidazol-2-ones 71 and 7m. The efficient derivatization of the unprotected N atom of these monoprotected cyclic urea derivatives was accomplished by treating with activated and unactivated halides in the. presence of K2CO3 or exposure to alcohols under Mitsunobu conditions. In several cases, mixtures of O- and N-alkylated products were produced which were readily separated by chromatography. Alkylation of 7h with activated halides, using K2CO3 in CH3CN at reflux, occurred without protecting group equilibration; however, a mixture of isomeric alkylated products was obtained when 7h was heated at 110 degrees C in DMF with cyclohexylmethyl bromide in the presence of K2CO3 as the base. Derivatization of 7h under Mitsunobu reaction conditions proceeded with retention of the topological substituent relationships. Subsequent removal of the alkoxycarbonyl moiety afforded monoalkylated cyclic urea derivatives.

  DOI：

  10.1021/jo00111a014

文献信息

• [EN] D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE<br/>[FR] ANTAGONISTES D2, PROCÉDÉS DE SYNTHÈSE ET MÉTHODES D'UTILISATION
  申请人：ALTOS THERAPEUTICS LLC

  公开号：WO2011160084A1

  公开（公告）日：2011-12-22

  Provided are D2 or D3 antagonist compounds and pharmaceutical compositions of formula I and pharmaceutically acceptable salts thereof, or isomers thereof, wherein R1, R2 and R3 are as defined herein. The invention further comprises methods for making the compounds of the invention and methods for the treatment of conditions mediated by the dopamine D2 or D3 receptor from the compounds of the invention.

  提供了D2或D3拮抗剂化合物以及公式I和其药学上可接受的盐或异构体的药物组合物，其中R1、R2和R3如本文所定义。该发明还包括制备该发明化合物的方法以及利用该发明化合物治疗由多巴胺D2或D3受体介导的疾病的方法。
• Identification and characterization of benzo[d]oxazol-2(3H)-one derivatives as the first potent and selective small-molecule inhibitors of chromodomain protein CDYL
  作者：Lixin Yang、Yongqing Liu、Minghua Fan、Guiwang Zhu、Hongwei Jin、Jing Liang、Zhenming Liu、Zhuo Huang、Liangren Zhang

  DOI：10.1016/j.ejmech.2019.111656

  日期：2019.11

  [d]oxazol-2(3H)-one analogs as the first potent and selective small-molecule inhibitors of chromodomain Y-like (CDYL), a histone methyllysine reader protein. The binding conformation between the chromodomain of CDYL and the modified peptidomimetics was studied via molecular docking and dynamic simulations, facilitating subsequent virtual screening of tens of hits from Specs chemical library validated by SPR technique

  组蛋白翻译后修饰（PTM）的表观遗传“阅读器”的化学探针已成为在生理学和病理学上对其靶蛋白进行机理和功能研究的强大工具。然而，仅开发了有限的“阅读器”探针，这限制了我们对这些大分子及其在细胞或动物中的作用的理解。在这里，我们报道了一种结构导向的方法来开发和表征苯并[d]恶唑-2（3H）-类似物，作为第一个有效的和选择性的小分子抑制剂，称为色域Y样（CDYL），一种组蛋白甲基赖氨酸阅读器蛋白。通过分子对接和动态模拟研究了CDYL的色域与修饰的拟肽之间的结合构象，便于随后从Specs化学文库中通过SPR技术验证的数十个命中点进行虚拟筛选（KD值：从271.1μM到5.4μM）。43种化合物的进一步设计和合成有助于解释结构-活性关系（SAR），这导致发现了新型CDYL小分子抑制剂。发现了化合物D03（KD：0.5μM），并且在其他色域蛋白中表现出优异的选择性，包​​括CDYL2（> 140倍），CDY1（未观察到结合）和CBX7（>
• [EN] BENZIMIDAZOLONE ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX A BASE DE BENZIMIDAZOLONE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2002026228A1

  公开（公告）日：2002-04-04

  The present invention concerns antiviral compounds, their compositions, and use in the treatment of viral infections. More particularly, the invention provides benzimidazonone derivatives for the treatment of respiratory syncytial virus infection.

  本发明涉及抗病毒化合物、它们的组成以及在治疗病毒感染方面的应用。更具体地，本发明提供苯并咪唑酮衍生物用于治疗呼吸道合胞病毒感染。
• SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE
  申请人：Arndt Torsten

  公开号：US20120172335A1

  公开（公告）日：2012-07-05

  The present invention relates to novel benzimidazolone derivatives of the general formula (I) in which the substituents R 1 , R 2 , R 3 , A 1 , A 2 , and B are as defined in claim 1 , medicaments comprising these, and the use thereof for the prophylaxis and/or treatment of vasopressin-dependent diseases.

  本发明涉及一种新型苯并咪唑酮衍生物，其通式为（I），其中取代基R1、R2、R3、A1、A2和B如权利要求书所定义，包括这些衍生物的药物以及它们在抗利尿激素依赖性疾病的预防和/或治疗中的应用。
• Substituted benzimidazolone derivatives, medicaments comprising them and their use
  申请人：Abbott GmbH & Co. HG

  公开号：US08119676B2

  公开（公告）日：2012-02-21

  The present invention relates to novel benzimidazolone derivatives of the general formula (I) in which the substituents R1, R2, R3, A1, A2, and B are as defined in claim 1, medicaments comprising these, and the use thereof for the prophylaxis and/or treatment of vasopressin-dependent diseases.

  本发明涉及一种新型苯并咪唑酮衍生物，其一般式为(I)，其中取代基R1、R2、R3、A1、A2和B的定义如权利要求书1所述，包括这些衍生物的药物，以及用于预防和/或治疗利尿激素依赖性疾病的使用。